Evaluation of COVID-19 Vaccines: Is Hesitancy for Some Vaccines Evidence-Based ?

This discussion examines the complexities of comparing COVID-19 vaccines and the factors contributing to public hesitancy. It underscores why efficacy percentages alone can be misleading, pointing to differences in trial settings, population demographics, and circulating variants. Although rare side effects like blood clots have caused concern, the risk of severe COVID-19 remains significantly higher. The content emphasizes the importance of context-driven decision-making and encourages a more informed and balanced understanding of vaccine safety and effectiveness.